TARA - NASDAQ
Protara Therapeutics, Inc.
$4.22
-1.2%Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
At a Glance
Live SnapshotProtara Therapeutics, Inc. Management Team
Mr. Patrick Fabbio M.B.A.
Chief Financial Officer
Compensation
$782,409
Dr. Leonardo Viana Nicacio M.D.
Chief Medical Officer
Dr. Shane Williams Ph.D.
Chief People Officer
Dr. Jacqueline Zummo M.B.A., M.P.H., Ph.D.
Co-Founder & Chief Scientific Operations Officer
Compensation
$962,033
Mr. Jesse Shefferman
Co-founder, Chief Executive Officer, President & Director
Compensation
$1,136,549
Ms. Mary J. Grendell J.D.
General Counsel & Corporate Secretary
Ms. Justine O'Malley
Senior Vice President of Investor Relations & Corporate Affairs
Ms. Hannah Fry
Vice President, Principal Accounting Officer & Controller
Protara Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $626K and sold $125K worth of TARA shares, resulting in $501K of net buying activity.
3 Months
0
0.00
23.7K
124.99K
-125K
-$125K
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
192.0K
625.92K
0
0.00
+626K
+$626K
Top Buyers
Garceau Roger
Director
$78K
Smith Cynthia
Director
$78K
Flannelly Barry P
Director
$78K
Beshar Luke M
Director
$78K
Sargen Gregory
Director
$78K
Top Sellers
Zummo Jacqueline
Officer: Chief R&D Officer
$125K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $501K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
TARA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 12, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 25, 2025 | June 11, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 26, 2024 | June 07, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 26, 2023 | June 07, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 27, 2022 | June 08, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 27, 2021 | June 09, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 23, 2020 | June 09, 2020 | 2020 | |
DEF 14A DEF 14A 2018 N/A | April 26, 2018 | June 08, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | July 13, 2017 | July 31, 2017 | 2017 | |
DEF 14A DEF 14A 2017 N/A | April 27, 2017 | June 20, 2017 | 2017 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.